ArticleLasers in medical science2025
Sublethal laser interstitial thermal therapy leads to confined neurological deficits and glioblastoma regression.
Article in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Laser Interstitial Thermal Therapy for High-Grade Gliomas: Current Evidence, Clinical Applications and Emerging Role of Artificial Intelligence.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeLaser interstitial thermal therapy (LITT) is a novel, minimally invasive treatment for intracranial lesions. In addition to a direct ablation effect, it can cause sublethal damage at mild temperatures. The impact of sublethal damage on the eloquent brain cortex, neural function, and growth of glioblastomas has not yet been fully investigated.
methodThis study involved a comparative assessment conducted before and after sublethal LITT treatment in an animal model. Pre-LITT and post-LITT behavioral tests were conducted to evaluate neural function. Magnetic resonance imaging data and brain samples were collected to evaluate morphological and pathological alterations in the brain tissue. IBA-1 staining was performed to examine the effect of the microglial cell-induced inflammatory response on cortical damage. Blood-brain barrier (BBB) disruption tests were conducted to evaluate BBB integrity. Finally, tumor-bearing rats were used to assess the tumor-suppressive effects of sublethal LITT.
resultsNeuronal deterioration was observed immediately after sublethal LITT treatment, which recovered within 4 weeks. No significant variation was observed in motor, memory, or cognitive function before and after the unilateral or contralateral LITT intervention. Tumor suppression was evident with sublethal LITT intervention. BBB integrity was initially disrupted but recovered 2 weeks later.
conclusionThe impact of sublethal LITT on the eloquent cortex appears to be reversible, with no observed effects on neural function. Sublethal LITT treatment may effectively suppress tumors and disrupt the BBB.
Indexed as
Identifiers
40646361What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.